drugset / Trial / NCT02217800
The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to assess the effect of the different continuous s.c. infusion treatments on the human growth hormone (hGH) levels in untreated acromegalic patients in comparison to a standard dose of octreotide. In addition, the pharmacokinetic profile and the safety and tolerability of DG3173 after continuous s.c. infusion will be evaluated.
Timeline
- Start
- 2013-11
- Primary completion
- 2014-03
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Octreotide | Peptide | 300 ug | Subcutaneous |
| Subject | veldoreotide | Protein / enzyme biologic | 920 ug | Subcutaneous |
| Subject | veldoreotide | Protein / enzyme biologic | 2760 ug | Subcutaneous |
| Subject | veldoreotide | Protein / enzyme biologic | 5520 ug | Subcutaneous |